

U.S. NUCLEAR REGULATORY COMMISSION

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

*PC 02120*

*317033*

<p style="text-align: center;">Licensee</p> <p>1. Wabash County Hospital</p> <p>2. 710 North East Street Wabash, IN 46992</p>	<p>In accordance with letter dated <b>March 21, 2008</b>,</p> <p>3. License number 13-18570-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date <b>September 30, 2014</b></p> <p>5. Docket No. 030-13881 Reference No.</p>
---	--

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. As needed

9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
  - B. Any imaging and localization study permitted by 10 CFR 35.200.
  - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
  - D. In vitro studies.

CONDITIONS

- 10. A. Location of Use: 710 North East Street, Wabash, Indiana.
- B. License material (excluding generators and xenon-133) may also be used at temporary job sites in medical care facilities within the city limits of Wabash, Indiana.
- 11. Radiation Safety Officer: D. Michael Saint.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
13-18570-01

Docket or Reference Number  
030-13881

Amendment No. 22

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical uses:

Marvin Dean Dziabis, M.D.	10 CFR 35.100, 35.200 and 31.11.
Dean Gifford, M.D.	10 CFR 35.100, 35.200 and 31.11.
Brett A. Hagedorn, M.D.	10 CFR 35.100, 35.200 and 35.300.
John Rock, M.D.	10 CFR 35.100, 35.200 and 31.11.
Rik Stephens, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
James C. Wehrenberg, M.D.	10 CFR 35.100, 35.200 and 31.11.
James A. Arata, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
David B. Janizek, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Christine Anne Tremper, M.D.	<b>10 CFR 35.100, 35.200, and 35.300 (limited to the treatment of hyperthyroidism).</b>
Randall J. Phillips, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
John Pasalich, M.D.	10 CFR 35.100, 35.200 and 35.300.
Stephen R. Phillip, M.D.	10 CFR 35.100, 35.200 and 35.300.
Marc Thomas, M.D.	10 CFR 35.100, 35.200 and 35.300.
Diane D. Daly, M.D.	10 CFR 35.100, 35.200 and 35.300.
John L. Bormann, M.D.	10 CFR 35.100, 35.200 and 35.300.
Michael E. Parker, M.D.	10 CFR 35.100, 35.200 and 35.300.
Pamela Lee Strange, M.D.	10 CFR 35.100, 35.200 and 35.300.
Michael W. Tanksley, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding thyroid carcinoma therapy).
Joseph R. Decamp, M.D.	<b>10 CFR 35.100, 35.200 and 35.300 (limited to the treatment of hyperthyroidism).</b>

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
13-18570-01Docket or Reference Number  
030-13881

Amendment No. 22

John R. Kim, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
Frederick N. Vandeman, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
Andre Byard Stovall, M.D.	10 CFR 35.100, 35.200 and 35.300.
Christopher Michael Kowalski, M.D.	10 CFR 35.100 and 35.200.
Gina W. Hook, M.D.	10 CFR 35.100 and 35.200.
Richard W. Sibley, M.D.	10 CFR 35.100, 35.200 and 35.300.
Dakshesh S. Patel, M.D.	10 CFR 35.100 and 35.200.
Shilpa S. Kashyap, M.D.	10 CFR 35.100 and 35.200.
Eric V. Heatwole, M.D.	10 CFR 35.100 and 35.200.
Shawn Johnson, M.D.	10 CFR 35.100, 35.200 and 35.300.
<b>Daniel LaMar, M.D.</b>	<b>10 CFR 35.100 and 35.200.</b>
<b>Linda Hippenhammer, M.D.</b>	<b>10 CFR 35.100 and 35.200.</b>

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
13-18570-01

Docket or Reference Number  
030-13881

Amendment No. 22

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated March 25, 2004; and
  - B. Letters dated September 16, 2004, and **March 21, 2008.**

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUN 27 2008

By *Colleen Carol Casey*  
Colleen Carol Casey  
Materials Licensing Branch  
Region III